MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
The MOMENTUM trial randomized symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor to receive either momelotinib or danazol.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (1)
Cited by (1)
Source provenance
- openalex
- last seen: 2026-05-10T11:12:16.133615+00:00
- unpaywall
- last seen: 2026-11-05T06:08:55.941966+00:00
License: CC0
· commercial use OK